The rally occurred in the immediate aftermath of the U.S. midterm elections. Market analysts noted that after weeks of inflation concerns, rising bond yields, and geopolitical uncertainty, investors appeared ready to assume greater risk. The prevailing market view suggests that political disruptions from Washington may diminish, potentially triggering a relief rally. However, experts cautioned that investors should remain mindful of persistent risks, including Middle East tensions, inflationary pressures, and uncertainties surrounding the artificial intelligence sector.
Sector performance was mixed but generally positive. Tech stocks led the charge, with Logitech surging 8.7 percent, a move attributed to strong gains by its counterpart Apple. Alcon rose 5.8 percent, while UBS gained 4.6 percent. The bank’s shares benefited from a Bloomberg report detailing a new compromise proposal in the ongoing debate over capital adequacy regulations. Speculation also persisted regarding a potential sale of UBS, with Morgan Stanley cited as a possible buyer. Partners Group added 4.2 percent to its valuation.
Conversely, ABB fell 2.8 percent. Market observers indicated that investors were reassessing the impact of the U.S. political shift on specific sectors, with concerns emerging that the new political balance might lead to stricter regulation of the AI sector. This uncertainty also weighed on data center expansion prospects, affecting industrial stocks like ABB.
In a separate development, Sandoz Group AG announced that it will be included in the SMI following the regular index review by SIX. The inclusion, effective after the market close on 18 September 2026, marks a significant milestone for the company, which listed in 2023. Sandoz, described as a global leader in affordable medicines, has steadily advanced through Swiss equity rankings, moving up within the Swiss Leader Index (SLI) and SPI.
Richard Saynor, Chief Executive Officer of Sandoz, stated that the inclusion illustrates the company’s evolution as an independent entity and growing investor confidence in its strategy. Remco Steenbergen, Chief Financial Officer, added that greater visibility in capital markets strengthens the company’s ability to invest in sustainable growth and broaden access to affordable medicines. The SMI comprises the 20 largest and most liquid stocks listed on the SIX Swiss Exchange and serves as the primary benchmark for Swiss equities.
While the SMI’s recent surge to 14,117.75 points in a previous session was driven by defensive heavyweights like Nestlé (+3.3%), Roche (+2.1%), and Novartis (+0.8%), the latest record high reflects a broader risk appetite. Traders have warned that the equity environment remains characterized by volatility, citing declining trading volumes and ongoing geopolitical uncertainties. The next major index adjustment will take effect on 21 September 2026, incorporating Sandoz into the blue-chip lineup.
